BACKGROUND: Cytokines are intercellular hormones, believed to play a functional role in the natural history of various malignant diseases. In vitro and in vivo studies have indicated that interleukin 6 (IL-6) may provide autocrine and paracrine growth stimulation in ovarian cancer cells. METHODS: In the present study we measured IL-6 in the serum of 73 patients with FIGO stage I to IV ovarian cancer. Enzyme-linked immunosorbent assay (ELISA) was used to determine IL-6 serum levels. Results were correlated to clinical data. Serum levels of IL-6 were additionally evaluated in a panel of 50 normal controls. RESULTS: Median serum levels of IL-6 in patients with ovarian cancer and normal controls were 55.6 (minimum 0, maximum 2869.0) pg/ml and 0.5 (minimum 0, maximum 2.14) pg/ml, respectively (Mann-Whitney U test, P = 0.0001). When serum levels of IL-6, taken prior to therapy, were grouped by FIGO stage, lymph node involvement, and grading of tumor cells, we found a statistically significant correlation with FIGO stage (Mann-Whitney U test, P = 0.04). Lymph node involvement and grading of tumor cells were not correlated with IL-6 levels. Elevated IL-6 serum levels prior to therapy were significantly correlated with poorer disease-free (log-rank test, P = 0.003) and overall survival (log-rank test, P = 0.01). CONCLUSION: Elevated IL-6 serum levels prior to therapy are correlated with a poor relapse-free and overall survival in ovarian cancer patients.
BACKGROUND: Cytokines are intercellular hormones, believed to play a functional role in the natural history of various malignant diseases. In vitro and in vivo studies have indicated that interleukin 6 (IL-6) may provide autocrine and paracrine growth stimulation in ovarian cancer cells. METHODS: In the present study we measured IL-6 in the serum of 73 patients with FIGO stage I to IV ovarian cancer. Enzyme-linked immunosorbent assay (ELISA) was used to determine IL-6 serum levels. Results were correlated to clinical data. Serum levels of IL-6 were additionally evaluated in a panel of 50 normal controls. RESULTS: Median serum levels of IL-6 in patients with ovarian cancer and normal controls were 55.6 (minimum 0, maximum 2869.0) pg/ml and 0.5 (minimum 0, maximum 2.14) pg/ml, respectively (Mann-Whitney U test, P = 0.0001). When serum levels of IL-6, taken prior to therapy, were grouped by FIGO stage, lymph node involvement, and grading of tumor cells, we found a statistically significant correlation with FIGO stage (Mann-Whitney U test, P = 0.04). Lymph node involvement and grading of tumor cells were not correlated with IL-6 levels. Elevated IL-6 serum levels prior to therapy were significantly correlated with poorer disease-free (log-rank test, P = 0.003) and overall survival (log-rank test, P = 0.01). CONCLUSION: Elevated IL-6 serum levels prior to therapy are correlated with a poor relapse-free and overall survival in ovarian cancerpatients.
Authors: Elizabeth L Kacel; Janae L Kirsch; Timothy S Sannes; Seema Patidar; Rachel Postupack; Sally Jensen; Shan Wong; Stephanie Garey; Stacy Dodd; Chantel M Ulfig; Christina S McCrae; Michael E Robinson; Jacqueline Castagno; Gregory S Schultz; Deidre B Pereira Journal: Health Psychol Date: 2019-08-01 Impact factor: 4.267
Authors: Helen E Burston; Oliver A Kent; Laudine Communal; Molly L Udaskin; Ren X Sun; Kevin R Brown; Euihye Jung; Kyle E Francis; Jose La Rose; Joshua Lowitz; Ronny Drapkin; Anne-Marie Mes-Masson; Robert Rottapel Journal: J Clin Invest Date: 2021-04-01 Impact factor: 14.808
Authors: Wei Wen; Wei Liang; Jun Wu; Claudia M Kowolik; Ralf Buettner; Anna Scuto; Meng-Yin Hsieh; Hao Hong; Christine E Brown; Stephen J Forman; David Horne; Robert Morgan; Mark Wakabayashi; Thanh H Dellinger; Ernest S Han; John H Yim; Richard Jove Journal: Mol Cancer Ther Date: 2014-10-15 Impact factor: 6.261
Authors: Zoya Yurkovetsky; Steven Skates; Aleksey Lomakin; Brian Nolen; Trenton Pulsipher; Francesmary Modugno; Jeffrey Marks; Andrew Godwin; Elieser Gorelik; Ian Jacobs; Usha Menon; Karen Lu; Donna Badgwell; Robert C Bast; Anna E Lokshin Journal: J Clin Oncol Date: 2010-04-05 Impact factor: 44.544
Authors: Bridget Charbonneau; Ellen L Goode; Kimberly R Kalli; Keith L Knutson; Melissa S Derycke Journal: Crit Rev Immunol Date: 2013 Impact factor: 2.214
Authors: Darren R Brenner; Dominique Scherer; Kenneth Muir; Joellen Schildkraut; Paolo Boffetta; Margaret R Spitz; Loic Le Marchand; Andrew T Chan; Ellen L Goode; Cornelia M Ulrich; Rayjean J Hung Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-06-24 Impact factor: 4.254